Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Teva
Dow
Daiichi Sankyo
Express Scripts
Chubb
Boehringer Ingelheim
US Department of Justice
Novartis
UBS

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,173,881

« Back to Dashboard

Which drugs does patent 9,173,881 protect, and when does it expire?

Patent 9,173,881 protects UPTRAVI and is included in one NDA.

This patent has twenty-four patent family members in sixteen countries.
Summary for Patent: 9,173,881
Title:Therapeutic compositions containing macitentan
Abstract: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. ##STR00001##
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: ACTELION PHARMACEUTICALS LTD. (Allschwil, CH)
Application Number:14/335,657
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,173,881

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-001 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,173,881

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/IB2008/053252Aug 13, 2008

Non-Orange Book US Patents Family Members for Patent 9,173,881

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,809,334 Therapeutic compositions containing macitentan ➤ Subscribe
9,597,331 Therapeutic compositions containing macitentan ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,173,881

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2011001625 ➤ Subscribe
Morocco 32614 ➤ Subscribe
South Korea 101678699 ➤ Subscribe
South Korea 20110045006 ➤ Subscribe
Japan 2015187148 ➤ Subscribe
Japan 5956026 ➤ Subscribe
Japan 5956025 ➤ Subscribe
Japan 2015180683 ➤ Subscribe
Japan 2011530581 ➤ Subscribe
Japan 5764061 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Queensland Health
Chubb
Cipla
McKesson
US Army
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot